Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Harmony Biosciences
Biotech
Harmony halts genetic disease program after phase 3 failure
After its cannabidiol gel failed a phase 3 trial in fragile X syndrome, Harmony has paused development of the asset in a different genetic disease.
Darren Incorvaia
Nov 4, 2025 12:45pm
Harmony's pivotal trial flops as placebo response causes discord
Sep 24, 2025 9:35am
Harmony buys Epygenix for $35M upfront
Apr 30, 2024 10:04am
Novavax CEO to retire after 12 years—Chutes & Ladders
Jan 13, 2023 9:30am
VenBio raises $550M to back its next batch of biotech startups
Jun 3, 2021 10:05am
